Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Eli Lilly (LLY) , which belongs to the Zacks Large Cap Pharmaceuticals industry.This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 14.54%.For the last reported quarter, Lilly came out with earnings of $7.02 per share versus the Zacks Conse ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Group 1: Company Performance - Hardman Johnston Global Equity Strategy reported a return of 2.91% for the fourth quarter of 2025, underperforming the MSCI AC World Net Index which gained 3.29% [1] - Eli Lilly and Company (NYSE:LLY) had a one-month return of -3.27% but saw a significant 29.28% increase in share value over the last 52 weeks, closing at $1,039.51 per share with a market capitalization of $931.876 billion on January 27, 2026 [2] - Eli Lilly's revenue grew by 54% in the third quarter of 2025 compared to the same period last year, indicating strong financial performance [4] Group 2: Key Contributors and Market Position - Eli Lilly was highlighted as a top contributor to relative performance in the fourth quarter, alongside Standard Chartered PLC and Hitachi, Ltd [3] - The company announced a deal with the U.S. administration that includes a three-year exemption from tariffs and the sale of GLP-1 therapies at discounted prices, which is expected to significantly expand its addressable patient population [3] - Eli Lilly continues to gain market share from Novo Nordisk in both diabetes and obesity markets, with strong prescription trends for its products Mounjaro and Zepbound [3] Group 3: Future Outlook - The anticipated approval and commercial launch of Orforglipron (oral GLP-1) in 2026 is expected to be a highly watched event with extremely high expectations [3] - Despite the strong performance of Eli Lilly, there are suggestions that certain AI stocks may offer greater upside potential and carry less downside risk [4]

Core Insights - U.S. drugmaker Eli Lilly has signed an agreement with Seamless Therapeutics, a Germany-based startup, valued at up to $1.12 billion to develop and commercialize treatments for hearing loss [1] Company Summary - Eli Lilly is expanding its portfolio by partnering with Seamless Therapeutics to address hearing loss, indicating a strategic move into the audiology market [1] - The agreement highlights Eli Lilly's commitment to innovative therapies and its willingness to invest significantly in emerging technologies [1] Industry Summary - The collaboration reflects a growing interest in the treatment of hearing loss, an area that has seen limited advancements compared to other medical fields [1] - The deal underscores the potential for significant market opportunities in the hearing loss treatment sector, which may attract further investments and research [1]

Core Insights - Novo Nordisk invested nearly $500 million in U.S. advertising for its GLP-1 drugs Wegovy and Ozempic during the first nine months of 2025, which is more than double the amount spent by Eli Lilly on its competing products [1] Company Summary - Novo Nordisk's advertising expenditure for GLP-1 drugs indicates a strong commitment to market presence and brand awareness in the competitive landscape of diabetes and obesity treatments [1] - Eli Lilly's lower advertising spend suggests a different strategic approach in promoting its rival medications, potentially impacting market share dynamics [1]

Advertising Expenditure - Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double Eli Lilly's expenditure on its rival medicines [1] - Novo spent an estimated $316 million on Wegovy and $169 million on Ozempic, reflecting increases of 54% and 44% respectively from the same period in 2024 [2] - Eli Lilly spent about $131 million on Zepbound and $83 million on Mounjaro during the same period, totaling approximately $214 million in advertising [3] Market Dynamics - The U.S. allows direct-to-consumer advertising of prescription medicines, which has been criticized for contributing to high medical costs [5] - A shift in availability for these medicines occurred in 2025 after a shortage in 2024, prompting Novo to increase advertising as supply improved [6] - Eli Lilly's Zepbound demonstrated a 47% greater weight loss compared to Wegovy in a head-to-head trial, which may explain Novo's increased advertising efforts to compete [7] Strategic Focus - Novo plans to advertise a new pill version of Wegovy immediately and utilize cash-pay, direct-to-consumer channels to boost sales [4]

中金研究 特朗普自2025年1月再次就任美国总统以来多次表示将采取措施推动美国药价降低，其多项举措与药企直接相关。根据ICER的报告，相比于2022年， 2024年经通胀调整后的新药标价（中位数）提高了24%，新药净价（中位数）提高了51%，药企的定价权依旧强势。总的来讲，我们认为，美国的高药 价与医保支付体系、PBM盈利机制，以及药企的定价权等因素密切相关，当前各方利益博弈之下，特朗普政府药价政策的实际效果与推进节奏存在不 确定性，影响相对有限。 点击小程序查看报告原文 美国医保体系的发展历程及现状 医疗服务成本高，医保覆盖率偏低 美国作为一个没有建立全民公共医保的发达国家，其以私人医疗保险为主体，市场力量为主导的医疗体系是一把双刃剑：一方面，通过市场竞争，将资金 与科技优势转化为医疗技术的发展，进而实现医疗产业的升级；另一方面，也导致当前美国医疗体系呈现出医疗服务成本高，医保覆盖面偏低，且医疗服 务效率有待提高的问题。 图表1：美国总医疗支出及其占GDP比重（1960-2023） 资料来源：CMS，中金公司研究部 ► 医疗服务成本： 在美国医疗总支出中，个人健康护理支出占绝对比重，其中，医院护理、专业医疗 ...

Eli Lilly and Company (NYSE:LLY) is one of the best US stocks to buy and hold in 2026. On January 20, Eli Lilly received FDA Breakthrough Therapy designation for sofetabart mipitecan. This status applies to the treatment of adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer whose disease has progressed despite prior therapies. Following positive Phase 1a/b data, this designation is expected to accelerate development timelines and increase regulatory engagement, significant ...

整理 | GLP1减重宝典内容团队 1月26日，药物临床试验登记与信息公示平台官网显示，礼来已登记一项 Brenipatide 注射液在成年抑郁症参与者中的 III 期临床研究。这是一 项名为 RENEW-MDD-1 的多中心、随机、双盲、平行组设计研究，核心目标是在成人抑郁症人群中，评估 Brenipatide 作为辅助治疗方案，相 较安慰剂在延迟疾病复发时间方面的有效性与安全性。根据登记信息，该研究计划在全球约200家研究机构开展，国内拟入组90例，国际拟入 组约1000例，显示出礼来在该适应症上的全球化推进力度。 Brenipatide 是一款 GLP-1 受体与 GIP 受体双重激动剂，也是礼来在替尔泊肽之后推出的第二款 GLP-1/GIP 双靶点新药。Insight 数据库显 示，这是全球首个启动抑郁症 III 期临床研究的 GLP-1 类产品，目前尚无其他同类机制药物在抑郁症领域进入临床阶段。这一进展，意味着 GLP-1 药物的作用边界正在从代谢疾病，进一步延伸至中枢神经系统相关疾病，具有明确的路径探索意义。 从产业背景看，礼来在双靶点 GLP-1 赛道的商业成功，为 Brenipatide 的跨 ...

Core Insights - The small nucleic acid drug sector is experiencing a significant surge, marking the beginning of a golden era driven by technological breakthroughs and capital enthusiasm [2][11][22] Industry Developments - On January 5, 2026, Sanofi's APOC3 siRNA drug Plozasiran was approved for domestic market use to treat hyperlipidemia [1] - On January 9, 2026, Rebio Biotech, known as "China's first small nucleic acid stock," successfully listed on the Hong Kong Stock Exchange, with its stock price soaring by 40% on the first day, leading to a market capitalization exceeding 13 billion HKD [1] - China National Pharmaceutical Group announced a 1.2 billion CNY acquisition of Hegia Biotech, securing the world's first clinically validated liver-targeted delivery platform capable of annual dosing [1] Market Trends - The global small nucleic acid drug market has seen nearly 100 business development (BD) collaborations in the past three years, with transaction numbers and amounts increasing annually, reaching over 30 BD deals in 2025 totaling nearly 30 billion USD [4][9] - Notable transactions in 2025 included Novartis acquiring Avidity Biosciences for 12 billion USD and multiple other significant deals involving RNA therapies [7][9] Clinical Advancements - Ionis's APOC3 ASO drug Olezarsen showed promising results in reducing triglyceride levels by up to 72% in patients with severe hypertriglyceridemia, leading to an increase in peak annual sales forecast from 1.5 billion USD to 2.5 billion USD [12] - GSK's ASO therapy Bepirovirsen is expected to be the first drug to achieve functional cure for chronic hepatitis B, with a peak annual sales potential of 2 billion USD [12] Emerging Opportunities - The small nucleic acid drugs are expanding into various therapeutic areas, including obesity and kidney diseases, with promising results from clinical trials demonstrating significant weight loss and metabolic health improvements [13][15] - The number of small nucleic acid drugs in development globally has surpassed 1,200, with siRNA and ASO therapies being the most prominent [17] Strategic Collaborations - Domestic companies are increasingly recognized for their innovative value in small nucleic acid drugs, with active BD transactions, including significant collaborations by Rebio Biotech and other firms [18][21] - Companies like Saintin Biotech are forming strategic partnerships with major pharmaceutical firms to advance their small nucleic acid drug pipelines [19] Conclusion - The convergence of technological advancements, capital influx, and successful clinical outcomes is propelling small nucleic acid drugs into a pivotal position within the pharmaceutical industry, with China poised to become a global innovation hub [22]